Cleveland Biolabs (CBLI) 3.20 $CBLI Cleveland BioLabs

New Post Public Reply Private Reply Replies (0) Message Board

Apr 22, 2015 at 8:00 PM

Cleveland Biolabs (CBLI) 3.20 $CBLI

Cleveland BioLabs Announces Acceptance of Entolimod Phase 1 Study Findings for Poster Presentation at ASCO
Marketwired - Wed Apr 22, 8:13AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that findings from a Phase 1 clinical study of entolimod (previously known as CBLB502) have been accepted for poster presentation at the 2015 annual meeting of the American Society of Clinical Oncology (ASCO), which will be held from May 29 - June 2 in Chicago, Illinois.
CBLI: 3.20 (+0.01)

Where Are The Investors Headed: Complementary Research on Clovis Oncology, DBV Technologies, Cleveland BioLabs, Arrowhead Research and Athenahealth
PR Newswire - Fri Apr 17, 7:25AM CDT
Editor Note: For more information about this release, please scroll to bottom.
DBVT: 25.66 (-0.01), ARWR: 6.87 (+0.13), CLVS: 85.04 (-1.36), CBLI: 3.20 (+0.01), ATHN: 120.16 (-1.35)

Cleveland BioLabs Receives Funding Recommendation From Department of Defense for Additional Development Proposal for Entolimod (CBLB502) as a Medical Radiation Countermeasure
Marketwired - Tue Apr 14, 6:30AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company received notice that a second proposal application to support further development of entolimod as a medical radiation countermeasure has been recommended for funding, subject to negotiations, by the Department of Defense (DoD) office of Congressionally Directed Medical Research Programs (CDMRP). This award is subject to successful negotiations and availability of funds.
CBLI: 3.20 (+0.01)

Cleveland BioLabs expects new composition of matter patent for CBLB612 in the US
M2 - Fri Apr 03, 6:38AM CDT
Biopharmaceutical company Cleveland BioLabs (NASDAQ:CBLI) disclosed on Thursday the allowance of a US patent application that covers composition of matter for CBLB612, an investigational drug in development for mobilisation of hematopoietic stem cells (HSCs) and for the prevention of chemotherapy-induced myelosuppression.
CBLI: 3.20 (+0.01)

Cleveland BioLabs Announces New U.S. Composition of Matter Patent for CBLB612
Marketwired - Thu Apr 02, 7:00AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the allowance of a U.S. patent application, to issue as U.S. Patent No. 9,006,183, covering composition of matter for CBLB612, an investigational drug in development for mobilization of hematopoietic stem cells (HSCs) and for the prevention of chemotherapy-induced myelosuppression.
CBLI: 3.20 (+0.01)

Cleveland BioLabs Announces Completion of Dosing in Phase 1 Study of CBLB612 in Russian Federation
Marketwired - Mon Mar 16, 6:30AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that a maximally tolerated dose has been reached and that dosing has been completed in a Phase 1 healthy subject study of CBLB612, an investigational drug in development for mobilization of hematopoietic stem cells (HSCs) and for the prevention of chemotherapy-induced myelosuppression.
CBLI: 3.20 (+0.01)

Cleveland BioLabs: A Reverse Split Low Floater With Catalysts
Jonathan Faison - at Seeking Alpha - Wed Mar 11, 1:41PM CDT

CBLI: 3.20 (+0.01), LPTN: 2.26 (unch)

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Therapeutic Pipeline Market Review H1 2015 Available at LifeScienceIndustryResearch.com
PRWeb - Tue Mar 10, 2:01PM CDT
The report "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Radiation Toxicity. Radiation Toxicity is an acute illness caused by a dose greater than 50 rads of penetrating radiation to most or all of the body in a short time, usually a matter of minutes. Common exposures to low-dose radiation, such as X-ray or CT examinations, don't cause radiation sickness. The symptoms are Nausea and vomiting, Diarrhea, Headache, Fever, Dizziness and disorientation, Weakness, fatigue, Hair loss, bloody vomit and stools, infections, poor wound healing, low blood pressure. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.lifescienceindustryresearch.com/ra...-2015.html .
PSTI: 2.80 (-0.03), ONTX: 2.48 (-0.05), CBLI: 3.20 (+0.01)

Cleveland BioLabs and Incuron Announce Growth of Curaxin CBL0137 Patent Portfolio With U.S. Composition of Matter Patent
Marketwired - Mon Mar 02, 6:30AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) and Incuron LLC, a joint venture between the CBLI and Bioprocess Capital Ventures, announce the issuance of a composition of matter patent for Curaxin CBL0137 in the U.S.
CBLI: 3.20 (+0.01)

Cleveland BioLabs' (CBLI) CEO Yakov Kogan on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 24, 12:18PM CST

CBLI: 3.20 (+0.01)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Feb 24, 8:16AM CST

FRO: 2.77 (-0.20), EYES: 13.26 (-0.06), BIOC: 3.15 (+0.02), AXN: 1.77 (+0.01), SPWR: 34.74 (+0.28), WIN: 8.41 (+0.06), ROSE: 22.02 (-0.50), GENE: 4.88 (-0.05), FSLR: 63.88 (+0.77), CHGG: 8.04 (unch), APRI: 1.77 (-0.02), CBAY: 5.00 (-0.14), CYRN: 3.31 (+0.01), CBLI: 3.20 (+0.01), TCON: 12.48 (+0.09), CAPN: 6.99 (-0.29)

Cleveland BioLabs reports Q4 results
Seeking Alpha - at Seeking Alpha - Tue Feb 24, 6:33AM CST

CBLI: 3.20 (+0.01)

Cleveland BioLabs Announces Receipt of Letter From NASDAQ Confirming Compliance With Minimum Bid Price Requirement
Marketwired - Wed Feb 18, 6:30AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on February 12, 2015, the Company received a letter from The NASDAQ Stock Market stating that the Company has regained compliance with Listing Rule 5550(a)(2), maintenance of a minimum bid price of $1.00.
CBLI: 3.20 (+0.01)

Cleveland BioLabs to Report Fourth Quarter and Fiscal Year 2014 Financial Results on February 24
Marketwired - Tue Feb 17, 9:36AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on February 24, 2015, it will report its financial results for the fourth quarter and fiscal year ended December 31, 2014, and will host a conference call at 10:00 a.m. ET.
CBLI: 3.20 (+0.01)

Cleveland BioLabs Announces Expansion of Entolimod Patent Portfolio With New Composition of Matter Patents
Marketwired - Wed Feb 11, 6:30AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the issuance of several new patents for entolimod in the U.S. and other countries, further strengthening its patent position.
CBLI: 3.20 (+0.01)

Cleveland BioLabs Announces Annual Meeting
Marketwired - Tue Feb 10, 6:01AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company will hold its 2015 Annual Meeting of Stockholders on April 14, 2015 in Buffalo, NY for stockholders of record as of March 5, 2015. The Company will distribute proxy materials to all eligible stockholders.
CBLI: 3.20 (+0.01)

Cleveland BioLabs to Present at 2015 BIO CEO & Investor Conference
Marketwired - Thu Feb 05, 6:31AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the 2015 BIO CEO & Investor Conference, February 9-10, in New York, NY.
CBLI: 3.20 (+0.01)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 11:44AM CST

CALX: 8.48 (-0.07), NES: 3.52 (-0.15), RVP: 4.11 (+0.01), RL: 136.39 (+0.44), SR: 0.91 (-0.12), MWA: 10.26 (+0.27), OHGI: 1.74 (-0.01), GENE: 4.88 (-0.05), CALI: 1.38 (+0.01), WPRT: 4.39 (+0.01), RSYS: 2.10 (-0.02), EGLT: 10.34 (-0.27), PACB: 5.90 (-0.07), ACHN: 10.01 (-0.13), BBSI: 42.01 (-1.23), AVEO: 2.04 (+0.12), CBLI: 3.20 (+0.01), ENG: 1.67 (+0.02), PLNR: 6.07 (+0.44)

Cleveland BioLabs Announces $4.2 Million Financing
Marketwired - Wed Feb 04, 8:06AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it has entered into definitive agreements with two institutional investors to purchase a total of $4.2 million of equity securities of the Company. The closing of the offering is expected to take place on or about February 6, 2015, subject to the satisfaction of customary closing conditions.
CBLI: 3.20 (+0.01), LTS: 3.56 (unch)

Cleveland BioLabs Announces Oncology Clinical Development Update for Entolimod
Marketwired - Thu Jan 29, 6:00AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced updates on oncology clinical development of entolimod (previously known as CBLB502).
CBLI: 3.20 (+0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Chicken Salad Chick Expands in Texas with New Opening

A New Flavor in Town: Chicken Salad Chick Opens in Texas When you hear about chicken salad, you probably don't think of Texas as its new frontier. But here we are, with Chicken Salad Chick spreading its wings in Victoria County. Come November 18, the folks down there will be in for a treat with the grand opening of the nation’s only fast casual chicken salad restaurant...

Pollo Campero's Care Cups Aid St. Jude's Mission

Pollo Campero’s Charitable Tradition Continues You know, in a world where headlines scream for attention, it's refreshing to see Pollo Campero sticking to their guns by backing St. Jude Children's Research Hospital. For eight solid years, this fried chicken champion has been dishing out more than just crispy delights; they're serving up hope, one cup at a time. Every...

Surgical Planning Associates Expands HipInsight Options

A Broader Horizon for Hip Surgery Planning Well, here we go—a medical technology play that's actually stirring things up, and not just blowing smoke. Surgical Planning Associates (SPA)—a name you might wanna keep an eye on—is turning heads with their HipInsight System. Just this week, they let it be known they've added five more implant systems to their 3D...

Moberg Pharma Secures U.S. Patent for MOB-015 Innovation

Moberg Pharma's Fresh U.S. Patent: A Game Changer? Moberg Pharma just snagged a U.S. patent for their whiz-bang dosing of MOB-015. Yup, the FDA’s go-ahead is still out of reach, but this patent is like hitting a full house on the river—sweetening the pot significantly. It's all about onychomycosis, or nail fungus, if you're not up on your medical terms. With patent...

UN Forum Unleashes LatAm CEO Coalition for Action

Latin America Takes Center Stage When the UN turns its spotlight on a region, you know there's something afoot. Right in Montevideo, Uruguay, the United Nations Global Compact gathered a hefty crowd of over 300 leaders from diverse backgrounds—think business, finance, government, and academia. What they were brewing wasn’t just talk; it was about driving real change...

Protalix to Reveal Q3 2026 Results Amid Rare Disease Push

Looking Ahead to Protalix's Q3 Revelation Nobody's pretending it's a cakewalk to stay ahead in the biopharma sector, especially when you're tangoing with the unpredictable world of rare disease therapeutics. But here we are, with Protalix BioTherapeutics scheduling their third-quarter financial results announcement for November 10, 2026. If you've been tracking them—or...

Wincomm & Portwell Unveil Medical AI Tech at MEDICA 2026

MEDICA 2026: Wincomm and Portwell Join Forces November's got one heck of an event lined up with MEDICA 2026, where Wincomm and Portwell are teaming up to showcase what they've got up their sleeves in medical AI computing. This whole shebang runs from November 16 to 19, with their setup in Hall 12, Stand C76, Düsseldorf, Germany. But why should investors care? Because...

Seaboard's Q3 Financials: A Mixed Bag for Investors

Eyeing Seaboard's Earnings: What's the Deal? Seaboard Corporation just dropped its earnings report for the third quarter, and boy, it's a doozy. The numbers show a mixed bag—like finding out your favorite team won, but your best player got benched with an injury. On the surface, we've got a rise in net sales, but dig a little deeper, and the cracks start to show. Sales...

Duni AB's 2027 AGM: Strategic Moves Amid Challenges

Navigating Choppy Waters: Duni's Market Stance Ever have one of those days when the market just refuses to cooperate no matter how much you hustle? Duni AB knows the feeling all too well. As this Swedish outfit gears up for its 2027 AGM, they're grinding through an array of challenges as prickly as a porcupine. Here's the scoop: their interim report from earlier this year...

Sesame Software's Game-Changer: Smooth CRM Switch

Why Leaving Salesforce Isn't as Crazy as It Sounds Stepping away from Salesforce isn't your run-of-the-mill decision for businesses. It’s more like abandoning ship, anticipating lurking dangers: losing cherished data, facing burdensome API restrictions, and fretting over years of trapped history. It’s not as simple as flipping a switch, and that’s what keeps most...